The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma

Leukemia Research

Volumn 39, Issue 3, 2015, Pages 380-387

  Martin, Sally K ^a,b,c,d   Gan, Zhen Ying ^a,c,d,e   Fitter, Stephen ^a,b,c,d   To, Luen B ^f   Zannettino, Andrew C W ^a,b,c,d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b HANSON INSTITUTE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^f ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

BKM120; Bone; Multiple myeloma; PI3K

Indexed keywords

BUPARLISIB; N TERMINAL PROPEPTIDE TYPE 1 PROCOLLAGEN; PARAPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROCOLLAGEN; PROTEIN KINASE B; PROTEIN TRACP5; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; NVP-BKM120;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BONE ATROPHY; BONE DENSITY; BONE REMODELING; CELL CYCLE PROGRESSION; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC50; IMMUNOCOMPETENCE; IN VITRO STUDY; IN VIVO STUDY; INFANT; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; PLASMA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; TIBIA; TRABECULAR BONE; TREATMENT DURATION; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE DISEASES; C57BL MOUSE; CELL CYCLE; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; OSTEOLYSIS; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

AMINOPYRIDINES; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE DISEASES; CELL CYCLE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICE; MICE, INBRED C57BL; MORPHOLINES; MULTIPLE MYELOMA; OSTEOCLASTS; OSTEOLYSIS; PHOSPHATIDYLINOSITOL 3-KINASES; TUMOR BURDEN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924042929     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.12.015     Document Type: Article

References (33)

1. Roodman G.D. Myeloma bone disease: pathogenesis and treatment. Oncology (Williston Park) 2005, 19(8):983-984. 986.
2. Giuliani N., Rizzoli V., Roodman G.D. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006, 108(13):3992-3996.
3. Farrugia A.N., Atkins G.J., To L.B., et al. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 2003, 63(17):5438-5445.
4. Heider U., Hofbauer L.C., Zavrski I., Kaiser M., Jakob C., Sezer O. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochem Biophys Res Commun 2005, 338(2):687-693.
5. Zannettino A.C., Farrugia A.N., Kortesidis A., et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 2005, 65(5):1700-1709.
6. Noll J.E., Williams S.A., Tong C.M., et al. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica 2013.
7. Silvestris F., Cafforio P., Calvani N., Dammacco F. Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol 2004, 126(4):475-486.
8. Silvestris F., Cafforio P., Tucci M., Grinello D., Dammacco F. Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br J Haematol 2003, 122(1):39-52.
9. Luo J., Manning B.D., Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4(4):257-262.
10. Abroun S., Ishikawa H., Tsuyama N., et al. Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha. Blood 2004, 103(6):2291-2298. [corrected].
11. Ge N.L., Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000, 96(8):2856-2861.
12. Hideshima T., Nakamura N., Chauhan D., Anderson K.C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001, 20(42):5991-6000.
13. Pene F., Claessens Y.E., Muller O., et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002, 21(43):6587-6597.
14. Kratchmarova I., Blagoev B., Haack-Sorensen M., Kassem M., Mann M. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science 2005, 308(5727):1472-1477.
15. Fitter S., Dewar A.L., Kostakis P., et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008, 111(5):2538-2547.
16. Vinals F., Lopez-Rovira T., Rosa J.L., Ventura F. Inhibition of PI3K/p70 S6K and p38 MAPK cascades increases osteoblastic differentiation induced by BMP-2. FEBS Lett 2002, 510(1-2):99-104.
17. Gingery A., Bradley E., Shaw A., Oursler M.J. Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem 2003, 89(1):165-179.
18. Lee S.E., Woo K.M., Kim S.Y., et al. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 2002, 30(1):71-77.
19. Sugatani T., Hruska K.A. Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem 2005, 280(5):3583-3589.
20. Vandyke K., Dewar A.L., Diamond P., et al. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. J Bone Miner Res 2010, 25(8):1759-1770.
21. Fitter S., Vandyke K., Gronthos S., Zannettino A.C. Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion. J Mol Endocrinol 2012, 48(3):229-240.
22. Zheng Y., Yang J., Qian J., et al. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl) 2012, 90(6):695-706.
23. Dallas S.L., Garrett I.R., Oyajobi B.O., et al. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 1999, 93(5):1697-1706.
24. Blade J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998, 102(5):1115-1123.
25. Fowler J.A., Mundy G.R., Lwin S.T., Edwards C.M. Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Res 2012, 72(9):2183-2189.
26. Vanderkerken K., Asosingh K., Willems A., et al. The 5T2MM murine model of multiple myeloma: maintenance and analysis. Methods Mol Med 2005, 113:191-205.
27. Chaudhary L.R., Hofmeister A.M., Hruska K.A. Differential growth factor control of bone formation through osteoprogenitor differentiation. Bone 2004, 34(3):402-411.
28. Hock J.M., Canalis E. Platelet-derived growth factor enhances bone cell replication, but not differentiated function of osteoblasts. Endocrinology 1994, 134(3):1423-1428.
29. Kubota K., Sakikawa C., Katsumata M., Nakamura T., Wakabayashi K. Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor. J Bone Miner Res 2002, 17(2):257-265.
30. Gundle R., Stewart K., Screen J., Beresford J.N. Isolation and culture of human bone-derived cells. Marrow stromal cell culture 1998, 43-66. Cambrige University Press, Cambridge. J.N. Beresford, M.E. Owen (Eds.).
31. Jaiswal N., Haynesworth S.E., Caplan A.I., Bruder S.P. Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J Cell Biochem 1997, 64(2):295-312.
32. Oyajobi B.O., Franchin G., Williams P.J., et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003, 102(1):311-319.
33. Ogawa T., Tokuda M., Tomizawa K., et al. Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteosarcoma (ROS 17/2.8) cells. Biochem Biophys Res Commun 1998, 249(1):226-230.